AGM/EGMApr 26, 2026, 05:30 AM
SVRA to Hold 2026 AGM; Proposes 600M Authorized Shares
AI Summary
Savara Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 4, 2026. Key proposals include the election of six directors, an amendment to increase authorized common stock from 300 million to 600 million shares, and an increase of 18.9 million shares for the 2024 Omnibus Incentive Plan. The company also provided an update on its investigational therapy, MOLBREEVI, with a US FDA Action Date of November 22, 2026, and highlighted recent financial strengthening through a $149.5 million equity financing and a $75 million royalty funding agreement.
Key Highlights
- 2026 Annual Meeting of Stockholders to be held virtually on June 4, 2026.
- Proposal to elect six directors to the Board.
- Proposal to increase authorized common stock from 300,000,000 to 600,000,000 shares.
- Proposal to increase shares for 2024 Omnibus Incentive Plan by 18,900,000.
- US FDA Action Date for MOLBREEVI Biologics License Application is November 22, 2026.
- Completed $149.5 million equity financing and entered $75 million royalty funding agreement.
- Amended debt facility to provide up to $75 million in additional debt funding upon FDA approval.